Details for Patent: 3,839,315
✉ Email this page to a colleague
Summary for Patent: 3,839,315
Title: | NOVEL PEPTIDES HAVING CHOLECYSTOKININ ACTIVITY AND INTERMEDIATES THEREFOR |
Abstract: | Novel peptide amides of the general formula R-Met-Gly-Trp-Met-Asp-Phe-NH.sub.2 wherein R represents L-aspartyl-O-sulfate-L-tyrosyl, L-aspartyl-L-arginyl-L-aspartyl-O-sulfate-L-tyrosyl, or isoleucyl-L-seryl-L-aspartyl-L-arginyl-L-aspartyl-O-sulfate-L-tyrosyl, and intermediates in the production thereof. The peptide amides of this invention as well as the pharmaceutically acceptable salts thereof have been found to possess cholecystokinin activity. |
Inventor(s): | Ondetti; Miguel A. (North Brunswick, NJ), Pluscec; Josip (East Brunswick, NJ), Sheehan; John T. (Middlesex, NJ), Jorpes; Johan E. (Stockholm, SW), Mutt; Viktor (Farsta, SW) |
Assignee: | E. R. Squibb & Sons, Inc. (New York, NY) |
Application Number: | 04/726,558 |
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 3,839,315
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 3,839,315
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 945145 | ⤷ Sign Up | |||
Canada | 987666 | ⤷ Sign Up | |||
Switzerland | 517702 | ⤷ Sign Up | |||
Germany | 1922185 | ⤷ Sign Up | |||
Denmark | 132074 | ⤷ Sign Up | |||
France | 2007810 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |